Novel cbg derivatives can reduce inflammation, pain and obesity

Natalya M. Kogan; Yarden Lavi; Louise M. Topping; Richard O. Williams; Fiona E. McCann; Zhanna Yekhtin; Marc Feldmann; Ruth Gallily; Raphael Mechoulam

doi:10.3390/molecules26185601

Novel cbg derivatives can reduce inflammation, pain and obesity

Natalya M. Kogan, Yarden Lavi, Louise M. Topping, Richard O. Williams, Fiona E. McCann, Zhanna Yekhtin, Marc Feldmann, Ruth Gallily, Raphael Mechoulam

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

Original language	English
Article number	5601
Journal	Molecules
Volume	26
Issue number	18
DOIs	https://doi.org/10.3390/molecules26185601
State	Published - Sep 2021
Externally published	Yes

Keywords

Anti-inflammatory
Cannabigerol
Cannabinoid
Obesity

Access to Document

10.3390/molecules26185601

Cite this

@article{66786e42e1834a05bd1f5c57672dca9f,

title = "Novel cbg derivatives can reduce inflammation, pain and obesity",

abstract = "Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.",

keywords = "Anti-inflammatory, Cannabigerol, Cannabinoid, Obesity",

author = "Kogan, {Natalya M.} and Yarden Lavi and Topping, {Louise M.} and Williams, {Richard O.} and McCann, {Fiona E.} and Zhanna Yekhtin and Marc Feldmann and Ruth Gallily and Raphael Mechoulam",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = sep,

doi = "10.3390/molecules26185601",

language = "אנגלית",

volume = "26",

journal = "Molecules",

issn = "1420-3049",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "18",

}

TY - JOUR

T1 - Novel cbg derivatives can reduce inflammation, pain and obesity

AU - Kogan, Natalya M.

AU - Lavi, Yarden

AU - Topping, Louise M.

AU - Williams, Richard O.

AU - McCann, Fiona E.

AU - Yekhtin, Zhanna

AU - Feldmann, Marc

AU - Gallily, Ruth

AU - Mechoulam, Raphael

PY - 2021/9

Y1 - 2021/9

N2 - Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

AB - Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

KW - Anti-inflammatory

KW - Cannabigerol

KW - Cannabinoid

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=85115229061&partnerID=8YFLogxK

U2 - 10.3390/molecules26185601

DO - 10.3390/molecules26185601

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34577072

AN - SCOPUS:85115229061

SN - 1420-3049

VL - 26

JO - Molecules

JF - Molecules

IS - 18

M1 - 5601

ER -

Novel cbg derivatives can reduce inflammation, pain and obesity

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this